Real‐world evidence has shown R‐CHOP to provide significant OS and PFS benefit over CHOP in Chinese patients aged ≥60 years and in those with non‐GCB‐subtype DLBCL [8, 9]; however, worse survival outcomes have been associated with high MYC/BCL2 co‐expression in Chinese patients with DLBCL treated with R‐CHOP [15]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.